Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection

Abstract We conducted an institutional study to compare the clinical and pathological efficacy between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle albumin–bound paclitaxel plus gemcitabine (nab‐P/G) for borderline resectable pancreatic cancer (BRPC) and locally advanced...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Adam R. Wolfe, Dhivya Prabhakar, Vedat O. Yildiz, Jordan M. Cloyd, Mary Dillhoff, Laith Abushahin, Dayssy Alexandra Diaz, Eric D. Miller, Wei Chen, Wendy L. Frankel, Anne Noonan, Terence M. Williams
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley 2020-07-01
Edice:Cancer Medicine
Témata:
chemotherapy
FOLFIRINOX
nab‐paclitaxel
neoadjuvant
pancreatic cancer
radiation
On-line přístup:https://doi.org/10.1002/cam4.3075
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky